Total Revenue
Boston Scientific Total Revenue decreased by 1.6% to $5.20B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11.6%, from $4.66B to $5.20B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows an upward trend with a 14.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand or successful price increases, while a decrease suggests market saturation or competitive pressure.
Detailed definition
The total amount of income generated by the sale of goods or services related to the company's primary operations. For a...
Peer comparison
Peer technology firms typically report this as Net Sales or Total Revenue, reflecting the scale of their market reach.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.08B | $2.93B | $3.13B | $3.03B | $3.24B | $3.17B | $3.24B | $3.39B | $3.60B | $3.53B | $3.73B | $3.86B | $4.12B | $4.21B | $4.56B | $4.66B | $5.06B | $5.07B | $5.29B | $5.20B |
| QoQ Change | — | -4.7% | +6.7% | -3.2% | +7.2% | -2.3% | +2.3% | +4.5% | +6.2% | -2.0% | +5.6% | +3.5% | +6.8% | +2.2% | +8.4% | +2.2% | +8.5% | +0.1% | +4.3% | -1.6% |
| YoY Change | — | — | — | — | +5.4% | +8.1% | +3.7% | +12.0% | +10.9% | +11.3% | +14.9% | +13.8% | +14.5% | +19.3% | +22.5% | +20.9% | +22.8% | +20.3% | +15.8% | +11.6% |
Product Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Interventional Cardiology & Vascular Therapies | — | — | — | — | — | — | — | $1.24B |
| Electrophysiology | $428.00M | $527.00M | $649.00M | $730.00M | $840.00M | $865.00M | $890.00M | $905.00M |
| Endoscopy | $676.00M | $678.00M | $691.00M | $673.00M | $737.00M | $747.00M | $759.00M | $736.00M |
| Urology | $525.00M | $532.00M | $630.00M | $633.00M | $676.00M | $682.00M | $718.00M | $646.00M |
| Cardiac Rhythm Management | $576.00M | $561.00M | $567.00M | $578.00M | $590.00M | $578.00M | $586.00M | $578.00M |
| Watchman | $379.00M | $380.00M | $413.00M | $425.00M | $486.00M | $512.00M | $535.00M | $506.00M |
| Neuromodulation | $282.00M | $268.00M | $300.00M | $271.00M | $303.00M | $293.00M | $332.00M | $318.00M |
| Global Interventional Cardiology (IC) Reporting Unit | $2.05B | $2.13B | $2.30B | $2.43B | $2.65B | $2.64B | — | — |
| Global Peripheral Interventions Pi Reporting Unit | $590.00M | $602.00M | $645.00M | $656.00M | $698.00M | $702.00M | — | — |
| Other | — | — | $0.00 | — | — | — | — | — |
| Total | $4.12B | $4.21B | $4.56B | $4.66B | $5.06B | $5.07B | $5.29B | $5.20B |
Interventional Cardiology & Vascular Therapies, Other are derived from annual filings.
Global Crm Reporting Unit, Global Interventional Cardiology (IC) Reporting Unit, Global Peripheral Interventions Pi Reporting Unit, Other were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $2.64B | $2.73B | $2.94B | $3.09B | $3.35B | $3.34B | $3.48B | $3.50B |
| MedSurg | $1.48B | $1.48B | $1.62B | $1.58B | $1.72B | $1.72B | $1.81B | $1.70B |
| Total | $4.12B | $4.21B | $4.56B | $4.66B | $5.06B | $5.07B | $5.29B | $5.20B |
Geographic Breakdown
| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| EMEA | $807.00M | $807.00M | $807.00M | $807.00M | $862.75M | $862.75M | $862.75M | $862.75M |
| Emerging Markets | $648.00M | $680.00M | $684.00M | $668.00M | $690.00M | $758.00M | $765.00M | $772.00M |
| Asia Pacific | $671.50M | $671.50M | $671.50M | $671.50M | $770.00M | $770.00M | $770.00M | $770.00M |
| Latin Americaand Canada | $156.00M | $156.00M | $156.00M | $156.00M | $169.50M | $169.50M | $169.50M | $169.50M |
| country_US excluding Other Net Sales | — | — | — | $2.55B | — | — | — | — |
| Total | $3.86B | $4.12B | $4.21B | $4.56B | $4.66B | $5.06B | $5.07B | $5.29B |
Asia Pacific, country_US excluding Other Net Sales, EMEA, Latin Americaand Canada are derived from annual filings.
Asia Pacific, country_US excluding Other Net Sales, EMEA, Emerging Markets, Latin Americaand Canada were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Total Revenue at Other Companies
Frequently Asked Questions
- What is Boston Scientific's total revenue?
- Boston Scientific (BSX) reported total revenue of $5.20B in Q1 2026.
- How has Boston Scientific's total revenue changed year-over-year?
- Boston Scientific's total revenue increased by 11.6% year-over-year, from $4.66B to $5.20B.
- What is the long-term trend for Boston Scientific's total revenue?
- Over 4 years (2021 to 2025), Boston Scientific's total revenue has grown at a 14.0% compound annual growth rate (CAGR), from $11.89B to $20.07B.
- What does total revenue mean?
- The total amount of money a company brings in from selling its products and services.